Key facts
- It has raised $27.4M; the latest was Later Stage VC ($27.4M) in Jan 2025.
- Notable investors include European Innovation Council, Nancy Lurie Marks Family Foundation, 21 Impact Labs, Kaldbakur, Sanos Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Arctic Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Arctic Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arctic Therapeutics
Operator of a drug discovery and development company intended to identify the genetic underpinnings of rare and common diseases. The company specializes in using bioinformatic approaches and AI to eliminate significant risks associated with traditional drug development, as well as sharply reducing the enormous cost, enabling healthcare operators to offer patients the ability to understand their genetic results and how these results guide individual therapies.
- Sector
- Healthcare
- HQ
- Reykjavik, Iceland
- Founded
- 2015
- Employees
- 21
- Website
- arctictherapeutics.com/
- Ownership
- Privately Held (backing)
Arctic Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arctic Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arctic Therapeutics in its N-PORT filings yet. We sweep new filings monthly.